AST-3424 clinical trials
AST-3424 is named as an intervention in 3 current clinical trials in our China and Mexico registers. 1 is recruiting patients now. The most common phase is Phase 1/2. The sponsor with the most trials is Zhejiang Hisun Pharmaceutical Co. Ltd (1). The most-studied condition is HCC - Hepatocellular Carcinoma.
How AST-3424 works
All drug targets →- Hepatocellular carcinomaPhase 2
- Acute lymphoblastic leukemiaPhase 1/2
- Lymphoblastic lymphomaPhase 1/2
- Prostate cancerPhase 1/2
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL4297474, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 12770, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for AST-3424
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of AST-3424
3 trials| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Phase IIb Study of AST-3424 in Patients With AKR1C3-high Expressing Advanced Hepatocellular Carcinoma
NCT07310173 · ClinicalTrials.gov ↗ · HCC - Hepatocellular Carcinoma
|
Phase 2 | Recruiting | Zhejiang Hisun Pharmaceutical Co. Ltd | China |
|
Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)
NCT04315324 · ClinicalTrials.gov ↗ · Recurrent T Acute Lymphoblastic Leukemia, Refractory T Acute Lymphoblastic Leukemia, Refractory T Lymphoblastic Lymphoma
|
Phase 1/2 | Active, closed | SWOG Cancer Research Network | Mexico |
|
A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors
NCT06239155 · ClinicalTrials.gov ↗ · Advanced Solid Tumors, Hepatocellular Carcinoma
|
Phase 1/2 | Active, closed | Ascentawits Pharmaceuticals, Ltd | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with AST-3424
7 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Zhejiang Hisun Pharmaceutical Co. Ltd | 1 |
| Ascentawits Pharmaceuticals, Ltd | 1 |
| SWOG Cancer Research Network | 1 |
By country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 2 | 1 |
| Clinical trials in Mexico | 1 | 0 |
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about AST-3424 trials
How many clinical trials are testing AST-3424?
3 current trials in our China and Mexico registers name AST-3424 (also registered as AKR1C3-activated Prodrug AST-3424) as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.
Are AST-3424 trials recruiting patients?
Yes. 1 of the 3 trials is recruiting: 1 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors AST-3424 clinical trials?
Zhejiang Hisun Pharmaceutical Co. Ltd (1), Ascentawits Pharmaceuticals, Ltd (1) and SWOG Cancer Research Network (1). The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how AST-3424 works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how AST-3424 works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists AST-3424 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.